Nasus Pharma Ltd. (NSRX)

Nasus Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.28	0.19	0.15
Cash & Short-Term Investments	0.28	0.19	0.15
Cash Growth	47.15%	25.32%	-
Other Receivables	0.12	-	-
Receivables	0.12	-	-
Prepaid Expenses	0.03	0.23	0.25
Restricted Cash	0.03	0.02	0.02
Total Current Assets	0.46	0.44	0.42
Long-Term Deferred Charges	0.26	-	-
Total Assets	0.72	0.44	0.42
Accounts Payable	0.65	0.66	0.77
Accrued Expenses	0.99	0.62	0.35
Short-Term Debt	1.8	2.46	1.57
Other Current Liabilities	0.49	0.51	0.51
Total Current Liabilities	3.93	4.24	3.2
Total Liabilities	3.93	4.24	3.2
Common Stock	0.02	0.02	0
Additional Paid-In Capital	9.43	7.32	7.29
Retained Earnings	-12.66	-11.13	-10.08
Shareholders' Equity	-3.21	-3.8	-2.79
Total Liabilities & Equity	0.72	0.44	0.42
Total Debt	1.8	2.46	1.57
Net Cash (Debt)	-1.52	-2.26	-1.42
Net Cash Per Share	-0.22	-0.32	-0.21
Filing Date Shares Outstanding	7.36	6.89	6.89
Total Common Shares Outstanding	7.36	6.89	6.89
Working Capital	-3.47	-3.8	-2.79
Book Value Per Share	-0.44	-0.55	-0.40
Tangible Book Value	-3.21	-3.8	-2.79
Tangible Book Value Per Share	-0.44	-0.55	-0.40

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q